Key Highlights

  • 272.96 is the six-month relative strength of Moderna (NASDAQ:MRNA), the highest of the four, with a one-month reading of 44.97. The shares fell 10.23% to USD 212.30 on October 16, 2026, for a USD 84.76 billion market capitalisation per published market data.
  • 246.07 is the six-month relative strength of Iovance (NASDAQ:IOVA), with a one-month reading of 46.19. Revenue guidance of USD 410 to 420 million was announced on September 29, 2026, and the shares fell 5.40% to USD 13.93 on October 16.
  • 185.00 is the six-month relative strength of Atlassian (NASDAQ:TEAM), with a one-month reading of 9.63. Fiscal fourth quarter revenue rose 28% per the company results of August 6, 2026, and the shares fell 5.05% to USD 206.16 on October 16.
  • 167.19 is the six-month relative strength of Quantum (NASDAQ:QMCO), but the one-month reading is negative 17.34. The 8-K dated October 9, 2026 reported the chief financial officer termination, and the shares fell 8.35% to USD 19.80 on October 16.

Moderna (NASDAQ:MRNA)

The six-month leader earned most of its strength recently, which makes it the least diverged of the four. Moderna (NASDAQ:MRNA) has a three-month relative strength of 241.19 after a 3.98% benchmark gain implied by other readings, which is 88.4% of the six-month reading (own arithmetic, a simple ratio). A six-month raw gain of 281.15% implies a base of USD 55.70 (own arithmetic). The drivers were the August 19, 2026 melanoma result for intismeran autogene with Keytruda and Nasdaq-100 inclusion before the October 9 open, after which the stock rose 8.3% on October 9 and fell 4.6% on October 12. Citi cut it to sell on September 30, 2026 with a USD 80 target. No company-specific catalyst was identified for the October 16 decline. What separates it: strength is both the highest and the most recent. So what: index demand is a one-time event, and consensus is Hold with an average target of USD 78.17 across 25 ratings. Overall survival data, regulatory timing and manufacturing scale-up are the next tests.

Iovance (NASDAQ:IOVA)

Revenue is the support, and the stock has already priced a long run of it. Iovance (NASDAQ:IOVA) has a three-month relative strength of 203.62 (own arithmetic), 82.7% of the six-month reading. A six-month raw gain of 254.33% implies a base of USD 3.93 (own arithmetic), and the stock closed at USD 8.99 on August 20, 2026, so USD 13.93 is 55.0% higher (own arithmetic). Second quarter revenue grew 65.7% on August 6, 2026, and the September 29 guidance raise lifted the midpoint 15.3% to USD 415 million (own arithmetic). The market capitalisation of USD 6.31 billion equals 15.2 times that midpoint. Short interest is 15.5% of float. What separates it: sales, not a pending readout, drive the six-month record. So what: the average target of USD 13.20 sits below the quote, and SARATOGA oral data is expected in late October. Equity issuance to fund a USD 391 million trailing loss would dilute holders.

Atlassian (NASDAQ:TEAM)

A third of this six-month record was earned before the latest three months. Atlassian (NASDAQ:TEAM) has a three-month relative strength of 124.94 (own arithmetic), 67.5% of the six-month reading, and a six-month raw gain of 194.03% implies a base of USD 70.12 (own arithmetic, not independently confirmed). The stock was USD 132.15 on January 27, 2026 amid fears of AI disruption, then rose more than 35% on August 7, 2026 after revenue of USD 1.766 billion rose 28%, cloud revenue rose 31% and free cash flow reached USD 475 million. Fiscal 2027 growth is guided to 13% from 26%, as Data Center revenue is guided down 17%. The average analyst target of USD 196.74 sits below the USD 206.16 quote, and the trailing price to earnings ratio is 204.66. What separates it: the strongest cash generation of the four. So what: the guided slowdown is company guidance, so delivery against it is the test. Chief executive Mike Cannon-Brookes plans to buy up to USD 250 million of Class A stock under a Rule 10b5-1 plan, and the fiscal first quarter report date was not confirmed.

Quantum (NASDAQ:QMCO)

The record is strongest where the recent pace is weakest. Quantum (NASDAQ:QMCO) has a three-month relative strength of 112.72 (own arithmetic), 67.4% of the six-month reading, and the one-month reading of negative 17.34 shows the stock trailing the benchmark since the CFO termination. June quarter revenue of USD 80.8 million rose 26%, adjusted EBITDA was USD 8.0 million, and debt of USD 104.3 million a year earlier was eliminated by June 30, 2026. Dilution was the price: 39.41 million shares against 22.0 million implied weighted shares in the quarter (own arithmetic). The company says it expects to meet or exceed guidance of USD 82.0 million, plus or minus USD 2.0 million, for the September quarter. What separates it: the only one-month reading below zero. So what: results estimated for November 12, 2026 and the 10-Q will test the reaffirmation. Lake Street raised its target to USD 29 from USD 24, and cash was USD 54.6 million at June 30, 2026.

Where Things Stand

Quantum (NASDAQ:QMCO) is the leader that is fading, while Moderna is not, though its 10.23% fall on October 16 shows how quickly that can change. Six-month relative strength ranks MRNA at 272.96, IOVA at 246.07, TEAM at 185.00 and QMCO at 167.19. Subtracting three-month from six-month readings leaves a gap of 31.77 for MRNA, 42.45 for IOVA, 54.47 for QMCO and 60.06 for TEAM (own arithmetic, simple differences), so the older gains are largest at Atlassian. All four trade above analyst targets or guided sales multiples that require continued execution. The next dated tests are SARATOGA data in late October, Iovance results on an estimated November 5, 2026 and Quantum results on an estimated November 12, 2026.